CA
NZ
UK
AU
IND
US
Eli Lilly (NYSE:LLY) shares were trading down 2.42% at $1,121.02 intraday, with a day range of $1,109.15 to $1,161.94 on volume of 2.07 million shares, despite the company announcing what would typically be viewed as positive news. The FDA granted Breakthrough Therapy designation to …
AbbVie (NYSE:ABBV) shares were trading down 1.35% at $247.54 intraday, with a day range of $244.71 to $256.20 on volume of 4.16 million shares, extending a decline that began following the company's second-quarter earnings report last week. Despite the pullback, Wall Street analysts have …
AstraZeneca (NYSE:AZN) shares are sliding sharply, down 6.87% at $157.99 intraday, with a day range of $153.41 to $159.16 on volume of 12.94 million shares, making it the worst performer on London's FTSE 100. The decline follows a Financial Times report that AstraZeneca has …
Bristol Myers Squibb (NYSE:BMY) shares are trading essentially flat today, up 0.37% at $65.55, with a day range of $64.14 to $68.10 on volume of 20.13 million shares, despite having spiked as much as 8% in premarket trading and touched an all-time high of …
DexCom (NASDAQ: DXCM), a leading provider of continuous glucose monitoring (CGM) systems, has regained Wall Street's attention after delivering an impressive technical breakout. Following several months of range-bound trading, the stock has accelerated sharply higher, reaching fresh 52-week highs and signaling renewed confidence among …
Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and genomics technologies, has regained investors' attention as its stock continues to outperform the broader healthcare sector. After spending much of last year recovering from a prolonged correction, shares have staged an impressive rally and …
Trend Structure: Strong Recovery, Steady Advance, and Consolidation Near Highs
Claritev Corporation (NYSE:CTEV) filed a Form 8-K under Regulation FD addressing a report that the US Department of Justice had opened a criminal antitrust investigation into it. The filing confirmed Claritev received a confidential grand jury subpoena from the DOJ's Antitrust Division in August …
The timing matters: second-quarter results landed after the close that afternoon, and nothing was filed with the Securities and Exchange Commission during the session. The move reads as positioning ahead of the print, not a reaction to it.
Health Catalyst (NASDAQ:HCAT) has spent 2026 dismantling parts of itself in the hope of rebuilding the rest: in April a restructuring that cuts close to a tenth of the workforce, in June an agreement to sell one of its software units outright.
Please wait processing your request...